NLRP3 and polycystic ovary syndrome: Post- treatment, increased miR-223 levels suppress NLRP3 activity, reducing inflammasome-driven inflammation and supporting metformin’s anti-inflammatory and metabolic benefits in obese PCOS patients [55,56].